Welcome to our dedicated page for Sol Gel Technolg SEC filings (Ticker: SLGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Skimming 10-K footnotes for microencapsulation data or tracking when Sol Gel’s executives sell shares can take hours. Clinical-stage dermatology companies like Sol Gel Technologies file dense reports packed with trial endpoints, FDA correspondence, and milestone payment clauses that are easy to miss.
Our platform turns that complexity into clarity. Stock Titan’s AI reads every Sol Gel Technologies annual report 10-K, quarterly earnings report 10-Q filing, and 8-K material events explained, then serves up plain-English takeaways—no pharmacology PhD required. Need Sol Gel Technologies insider trading Form 4 transactions or real-time alerts on Sol Gel Technologies Form 4 insider transactions real-time? We surface them seconds after they hit EDGAR. You’ll also find concise notes on R&D spend trends, partnership royalties, and how each pipeline update affects future cash burn, all inside our Sol Gel Technologies earnings report filing analysis.
Whether you’re monitoring Sol Gel Technologies proxy statement executive compensation ahead of a vote, comparing segment results across filings, or understanding Sol Gel Technologies SEC documents with AI for a rapid diligence check, every disclosure is here. Filter by form type, download exhibits, or jump straight to AI-powered summaries that highlight acne and rosacea trial milestones. From Sol Gel Technologies executive stock transactions Form 4 to a Sol Gel Technologies annual report 10-K simplified overview, you get the insight you need—faster than reading 200 pages of regulatory prose.
Sol-Gel Technologies Ltd. furnished a Notice of its 2025 Annual General Meeting and an accompanying proxy statement, together with a proxy card for shareholders of record as of September 29, 2025. The materials are incorporated by reference into the company’s registration statements on Form S-8 and Form F-3, ensuring the proxy disclosures are available to holders eligible to vote and to support related securities registrations. This filing supplies the formal voting materials shareholders need to review meeting matters and to submit proxies ahead of the meeting.
Opaleye Management Inc., Opaleye, L.P. and James Silverman reported beneficial ownership of 139,386 ordinary shares of Sol-Gel Technologies Ltd (SLGL), representing 5.00% of the class based on 2,785,787 shares outstanding. The shares are held by the Fund with voting and dispositive power shared among the reporting persons; no sole voting or dispositive power is reported. The filing states the stake was not acquired to change or influence control of the issuer and includes a joint filing agreement signed by James Silverman.
Sol-Gel Technologies Ltd. submitted a Form 6-K reporting two exhibits: a press release dated August 15, 2025 and unaudited condensed consolidated financial statements as of June 30, 2025 covering the three- and six-month periods ended June 30, 2025. The filing amends and restates the incorporation-by-reference language so that Exhibit 99.1 (except for four paragraphs immediately preceding the financial-results heading) and Exhibit 99.2 are incorporated into the company’s registration statements on Forms S-8 and F-3. The report is signed by the Chief Financial Officer, indicating the exhibits are being furnished to the SEC and made available to investors and registrants relying on the referenced registration statements.
FAQ
What is the current stock price of Sol Gel Technolg (SLGL)?
What is the market cap of Sol Gel Technolg (SLGL)?
